Stockscreener 앱 받기
23.31
1.02%
-0.24
시간 외 거래:
23.31
전일 마감가:
$23.55
열려 있는:
$23.62
하루 거래량:
941.08K
Relative Volume:
0.89
시가총액:
$1.55B
수익:
$8.30M
순이익/손실:
$-150.22M
주가수익비율:
-8.8295
EPS:
-2.64
순현금흐름:
$-122.93M
1주 성능:
-11.06%
1개월 성능:
-17.49%
6개월 성능:
-39.00%
1년 성능:
-19.87%
1일 변동 폭
$22.93
$23.76
1주일 범위
$22.93
$28.15
52주 변동 폭
$22.93
$53.18
Celldex Therapeutics Inc Stock (CLDX) Company Profile
명칭
Celldex Therapeutics Inc
전화
908-200-7500
주소
53 FRONTAGE ROAD, HAMPTON
CLDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| CLDX | 23.31 | 1.55B | 8.30M | -150.22M | -122.93M | -2.64 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-07 | 개시 | Citigroup | Buy |
| 2024-09-30 | 개시 | Goldman | Neutral |
| 2024-09-27 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | 개시 | Stifel | Buy |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2023-12-20 | 개시 | TD Cowen | Outperform |
| 2023-11-10 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | 개시 | Wells Fargo | Underweight |
| 2021-09-17 | 개시 | Jefferies | Buy |
| 2021-09-10 | 개시 | SVB Leerink | Outperform |
| 2021-07-22 | 개시 | Guggenheim | Buy |
| 2020-02-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-08-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-07 | 개시 | Aegis Capital | Buy |
| 2016-03-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2016-03-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2016-03-07 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2016-03-01 | 개시 | H.C. Wainwright | Buy |
| 2015-08-11 | 재확인 | Brean Capital | Buy |
| 2015-08-11 | 재확인 | Oppenheimer | Outperform |
| 2015-08-11 | 재확인 | ROTH Capital | Buy |
| 2015-06-02 | 재확인 | WBB Securities | Strong Buy |
| 2014-11-17 | 재확인 | ROTH Capital | Buy |
| 2014-03-04 | 재확인 | Oppenheimer | Outperform |
| 2013-07-08 | 재확인 | Cantor Fitzgerald | Buy |
| 2013-03-08 | 재확인 | Cantor Fitzgerald | Buy |
| 2013-02-26 | 재확인 | Oppenheimer | Outperform |
| 2013-01-10 | 재확인 | Cantor Fitzgerald | Buy |
| 2012-10-02 | 재확인 | Oppenheimer | Outperform |
| 2012-09-14 | 재확인 | Cantor Fitzgerald | Buy |
모두보기
Celldex Therapeutics Inc 주식(CLDX)의 최신 뉴스
Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month LowWhat's Next? - MarketBeat
Celldex stock touches 52-week low at $24.41 amid market shifts - Investing.com
Steven Cohen's Strategic Reduction in Celldex Therapeutics Holdi - GuruFocus.com
Eventide Asset Management's Strategic Acquisition in Celldex The - GuruFocus.com
Celldex Therapeutics' SWOT analysis: barzolvolimab stock potential in urticaria treatment - Investing.com India
Polar Capital Holdings Plc Reduces Stake in Celldex Therapeutics Inc - GuruFocus.com
Insider Buying: Celldex Therapeutics Inc (CLDX) President & CEO Acquires Shares - GuruFocus.com
Celldex Therapeutics (NASDAQ:CLDX) Trading 4.2% Higher Following Insider Buying Activity - Defense World
FMR LLC's Strategic Reduction in Celldex Therapeutics Inc Shares - GuruFocus.com
Insider Buying: Celldex Therapeutics, Inc. (NASDAQ:CLDX) CEO Buys 11,500 Shares of Stock - MarketBeat
Celldex Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Celldex (CLDX) to Present at Two Major Healthcare Investor Conferences in Q4 | CLDX Stock News - StockTitan
Leerink Partnrs Analysts Lower Earnings Estimates for CLDX - MarketBeat
What is HC Wainwright's Estimate for CLDX FY2024 Earnings? - MarketBeat
HC Wainwright Reiterates “Buy” Rating for Celldex Therapeutics (NASDAQ:CLDX) - Defense World
Wellington Management Group LLP's Strategic Acquisition in Celld - GuruFocus.com
FY2028 Earnings Forecast for CLDX Issued By Leerink Partnrs - MarketBeat
Celldex Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Celldex: Q3 Earnings Snapshot - San Antonio Express-News
Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Celldex Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Celldex stock touches 52-week low at $25.04 amid market shifts By Investing.com - Investing.com South Africa
Celldex Therapeutics (NASDAQ:CLDX) Reaches New 12-Month LowTime to Sell? - MarketBeat
Celldex stock touches 52-week low at $25.04 amid market shifts - Investing.com India
Celldex Therapeutics' Strong Cash Runway Supports Barzolvolimab's Path To Market - Seeking Alpha
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Emerald Advisers LLC Has $15.51 Million Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Evommune raises $115M to accelerate immune drug tests - Yahoo Finance
Market reaction to Intellia data suggests perfection remains bar for gene editing - BioCentury
Celldex Therapeutics (NASDAQ:CLDX) Trading Down 6%What's Next? - MarketBeat
Prurigo Nodularis Pipeline Update 2024: FDA Approvals, - openPR
Celldex shares hold as analyst maintains Buy rating By Investing.com - Investing.com UK
Celldex selloff creates buying opportunity, says Guggenheim - Yahoo Finance
Celldex shares gain as TD Cowen affirms Buy rating on robust Ph2 data - Investing.com UK
Analyst Expectations For Celldex Therapeutics's Future - Benzinga
HC Wainwright Reaffirms "Buy" Rating for Celldex Therapeutics (NASDAQ:CLDX) - MarketBeat
Celldex Therapeutics' SWOT analysis: barzolvolimab stock potential in urticaria - Investing.com India
Celldex Therapeutics (NASDAQ:CLDX) pulls back 6.1% this week, but still delivers shareholders fantastic 57% CAGR over 5 years - Yahoo Finance
Novo Holdings A S Grows Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria - ForexTV.com
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024 - The Manila Times
Celldex Therapeutics (CLDX): A Top Small-Cap Growth Stock with Promising Clinical Results - Insider Monkey
8 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey
TSX Global Gold Index (TTGD) QuotePress Release - The Globe and Mail
Celldex Therapeutics Inc (CLDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):